The International Initiative on Thrombosis and Cancer (ITAC), the international section of the Groupe Francophone Thrombose et Cancer (GFTC), presents this educational platform for specialist physicians and nurses involved in the care of patients with cancer who are at risk of venous thromboembolism (VTE) or with established VTE, including central venous catheter-related thrombosis (CRT).
Tuesday, March 7, 2017
Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with venous thromboembolism (VTE) can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis.
Full citation: Farge D, Bounameaux H, Bauersachs RM, Brenner B. Women, thrombosis, and cancer: A gender-specific analysis. Thromb Res 2017 Mar;151(Suppl 1):S21-9.
Monday, March 6, 2017
Monday, February 20, 2017
ITAC-CME is proud to announce that we have been granted a scientific session at the 2017 ISTH congress in Berlin on Sunday, July 9th, from 13:00-14:00 at the City Cube Messe Berlin, where all sessions that day take place. We hope you will join us!
Wednesday, October 5, 2016
ITAC-CME announced the publication of its updated 2016 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer in The Lancet Oncology. Endorsed by the International Society on Thrombosis and Haemostasis (ISTH), the guidelines include recommendations for treatment and prophylaxis for both in-hospital and outpatient cancer-associated VTE in specific cancer patient subgroups, and provides first-ever guidance for the appropriate use of the direct oral anticoagulants in the treatment of VTE in cancer patients.
Full citation: Farge-Bancel D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. 2016 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer. Lancet Oncol 2016 Oct;17(10):e452-e466.